Evidence map›Paper›PMID 41304838›Full record

ReviewPharmaceutics2025

Nanoparticles Used for the Delivery of RNAi-Based Therapeutics.

Tianrui Ren, Liang Ma, Ping Fu, Chuyue Zhang

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Target, silence, replace: a review on RNA-based drugs in modern medicine.Frontiers in cell and developmental biology · 2026
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tianrui RenDepartment of Nephrology, Kidney Research Institute, Science & Technology Department, West China Hospital of Sichuan University, Chengdu 610041, China.ORCID 0009-0008-1643-9225
Liang MaDepartment of Nephrology, Kidney Research Institute, Science & Technology Department, West China Hospital of Sichuan University, Chengdu 610041, China.ORCID 0000-0001-8327-7969
Ping FuDepartment of Nephrology, Kidney Research Institute, Science & Technology Department, West China Hospital of Sichuan University, Chengdu 610041, China.
Chuyue ZhangDepartment of Nephrology, Kidney Research Institute, Science & Technology Department, West China Hospital of Sichuan University, Chengdu 610041, China.ORCID 0000-0001-8510-3831

Funding

1.3.5 project for disciplines of excellence from West China Hospital of Sichuan University ZYGD23015National Natural Science Foundation of China 82200764Postdoctoral Research Fund from West China Hospital of Sichuan University 2023HXB092Sichuan Science and Technology Program 2025ZNSFSC1602Young Elite Scientists Sponsorship Program by CAST 2022QNRC001
6 · The paper itself

Abstract

RNA interference (RNAi) offers programmable, sequence-specific silencing via small interfering RNA (siRNA) and microRNA (miRNA), but clinical translation hinges on overcoming instability, immunogenicity, and inefficient endosomal escape. This review synthesizes advances in non-viral nanocarriers-liposomes, polymeric nanoparticles, and extracellular vesicles (EVs)-that stabilize nucleic acids, tune biodistribution, and enable organ- and cell-selective delivery. We highlight design levers that now define the field: ligand-guided targeting, stimuli-responsive release, biomimicry and endogenous carriers, and rational co-delivery with small molecules. Across major disease areas-cancer and cardiovascular, respiratory, and urological disorders-these platforms achieve tissue-selective uptake (e.g., macrophages, endothelium, and myocardium), traverse physiological barriers (including the blood-brain barrier and fibrotic stroma), and remodel hostile microenvironments or immune programs to enhance efficacy while maintaining favorable safety profiles. Early clinical studies reflect this diversity, spanning targeted nanoparticles, local drug depots, exosome and cellular carriers, and inhaled formulations, e.g., and converge on core phase-I endpoints (safety, maximum tolerated dose, pharmacokinetics/pharmacodynamics, and early activity). Looking ahead, priorities include good manufacturing practice scale, consistent manufacture-especially for EVs; more efficient loading and cargo control; improved endosomal escape and biodistribution; and rigorous, long-term safety evaluation with standardized, head-to-head benchmarking. Emerging directions such as in vivo EVs biogenesis, theragnostic integration, and data-driven formulation discovery are poised to accelerate translation. Collectively, nanoparticle-enabled RNAi has matured into a versatile, clinically relevant toolkit for precise gene silencing, positioning the field to deliver next-generation therapies across diverse indications.

Indexed as

exosomesliposomesmiRNApolymeric nanoparticlessiRNA

Identifiers

PMID41304838
PMCPMC12655160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.